News & Events

• May 20, 2022
  

  eCOA Consortium and PRO Consortium Announce Publication of Open Access Article

  C-Path’s eCOA Consortium and PRO Consortium are pleased to announce that “Recommendations for the Electronic Migration and Implementation of Clinician-Reported Outcome Assessments in Clinical Trials” was published online by Value in Health on April 2, 2022.  The article presents a framework for planning the migration and implementation of electronic ClinRO assessments, as well as best practice recommendations drawn from applicable practices...
• May 16, 2022
  

  The Critical Path for Parkinson’s Consortium Welcomes ESCAPE Bio

  The Critical Path for Parkinson’s Consortium (CPP) is thrilled to welcome our newest member, ESCAPE Bio, a clinical-stage company developing novel, precisely targeted therapies for genetic neurodegenerative diseases. We applaud ESCAPE Bio for their willingness to share data, consistent with CPP’s open science strategy for advancing drug development tools for Parkinson’s disease trials.
• April 28, 2022
  

  C-Path to Lead Novel Pre-Consortium Framework for Optimizing the Rare and Orphan Medical Product Lifecycle

  C-Path, in collaboration with one of the industry’s prominent rare and orphan (R&O) thought leaders, Maryna Kolochavina, Pharm.D., Ph.D., today announced the launch of unique pre-consortium collaboration, bringing together industry leaders and stakeholders to accelerate and standardize key constructs for the efficient development, approval and access to R&O medical products.

• April 14, 2022
  

  Longtime Pharmaceutical Executive to Lead C-Path’s Sickle Cell Disease Consortium

  Critical Path Institute (C-Path) has named Sergey Rakhilin, Ph.D., as Executive Director of its Critical Path for Sickle Cell Disease (CP-SCD) Consortium.

  Dr. Rakhilin joined C-Path after working in the pharmaceutical industry for 15 years. His work focused on various aspects of drug development, from target identification to clinical studies and biomarker analysis. He has contributed to the development of several treatments for muscle atrophy, hematological, and neurodegenerative diseases.

• April 7, 2022
  

  Doctor With Rare Disease And No Answers Decides To Find His Own Cure

  David Fajgenbaum was diagnosed with Castleman disease as a medical student. In Chasing My Cure, he recounts crowd-sourcing his own treatment with a global network of doctors, scientists and patients.